Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20564934 | 0.83 | KMT2A (0.36) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1208112 | 0.81 | MEN1 (0.37) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1209124 | 0.80 | MEN1 (0.36) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL21045877 | 0.77 | ALDH1A1 (0.47) | MEN1HTTKMT2A | |
| SCHEMBL1974011 | 0.77 | KMT2A (0.38) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL247809 | 0.74 | KDM4E (0.38) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL28449626 | 0.74 | L3MBTL1 (0.42) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL6005339 | 0.72 | TRPM8 (0.46) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL5655590 | 0.71 | CA12 (0.43) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL4414103 | 0.71 | IDO1 (0.52) | IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-02-04 | — | — | US | disclosed |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | RNASEH1, RNASE1, RNASEL | IDO1 115/4885AGXT 768/4885MEN1 1891/4885 |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | RNASEH1, RNASE1, RNASEL | IDO1 115/4885AGXT 768/4885MEN1 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.